A substance effective for treating immunopathy where MCP-1 is involved is provided. scFv having a high affinity to human MCP-1 was obtained using phage antibody technique. Based on information of VH chain and VL chain obtained from said scFv, a human anti-human MCP-1 antibody and a human anti-human MCP-1 antibody fragment are obtained. Said antibody and antibody fragment are expected to be useful as a medicament for treating inflammation and immunopathy caused by MCP-1.